923. EDP-938, A Respiratory Syncytial Virus (RSV) antiviral, demonstrates a high barrier to resistance in a human challenge study

BACKGROUND: RSV can cause substantial morbidity and mortality to populations at high risk and there are no approved direct acting antiviral treatments. EDP-938, an RSV nucleoprotein (N) inhibitor in Phase 2 clinical development, has demonstrated significant reductions in viral load and symptoms afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Levene, Rachel E, DeVincenzo, John, Conery, Annie, Ahmad, Alaa, Goodwin, Bryan, Or, Yat Sun, Rhodin, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677260/
http://dx.doi.org/10.1093/ofid/ofad500.968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677260/
http://dx.doi.org/10.1093/ofid/ofad500.968

Ejemplares similares